Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-27
2007-03-27
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S444000, C514S438000, C514S336000, C514S374000, C514S340000, C514S252130, C514S253110, C544S364000, C544S374000, C546S269400, C548S131000, C548S235000
Reexamination Certificate
active
10701186
ABSTRACT:
The present invention addresses substituted cyanothiophene derivatives of the formula I:as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.
REFERENCES:
patent: 3953468 (1976-04-01), Wechter et al.
patent: 4359474 (1982-11-01), Anderson et al.
patent: 4567196 (1986-01-01), Wierzbicki
patent: 4608384 (1986-08-01), Wierzbicki et al.
patent: 4831013 (1989-05-01), Francis
patent: 5422335 (1995-06-01), Hagen et al.
patent: 5776954 (1998-07-01), de Laszlo et al.
patent: 6048880 (2000-04-01), Kawai et al.
patent: 2004/0122016 (2004-06-01), Cao et al.
patent: 36 24 304 (1986-01-01), None
patent: 35 07 421 (1986-09-01), None
patent: 35 29 247 (1986-11-01), None
patent: 41 19 767 (2002-02-01), None
patent: 0 193 885 (1986-09-01), None
patent: 0 193 885 (1986-09-01), None
patent: 0 202 538 (1986-11-01), None
patent: 0 202 538 (1986-11-01), None
patent: 0 217 748 (1987-04-01), None
patent: 0 217 748 (1987-04-01), None
patent: 0 253 259 (1988-01-01), None
patent: 0 253 259 (1988-01-01), None
patent: 0 263 071 (1988-04-01), None
patent: 0 263 071 (1988-04-01), None
patent: 2 564 467 (1985-11-01), None
patent: 2 565 981 (1985-12-01), None
patent: 2002-50169 (2002-02-01), None
patent: WO 97/16442 (1997-05-01), None
patent: WO 98/04528 (1998-02-01), None
patent: WO 98/04528 (1998-02-01), None
patent: WO 98/21957 (1998-05-01), None
patent: WO 99/22108 (1998-05-01), None
patent: WO 99/22109 (1998-05-01), None
patent: WO 99/32448 (1998-07-01), None
patent: WO 99/01423 (1999-01-01), None
patent: WO 99/32448 (1999-07-01), None
patent: WO 99/46267 (1999-09-01), None
patent: WO 00/39088 (2000-07-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 01/36415 (2001-05-01), None
patent: WO 01/40223 (2001-06-01), None
patent: WO 01/40223 (2001-06-01), None
patent: WO 01/44226 (2001-06-01), None
patent: WO 01/46165 (2001-06-01), None
patent: WO 01/58890 (2001-08-01), None
patent: WO 02/18335 (2002-03-01), None
Al-Omron et al., Journal of Heterocyclic Chemistry (Sep.-Oct. 2002), 39(5), pp. 877-883.
Guillon, Jean, et al., “Synthesis of new pyrrolo[1,2-α]quinoxalines: potential non-peptide glucagon receptor antagonist”,Eur. J. Med. Chem,33, pp. 293-308 (1998).
Petersen, K. F., et al., “Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans”,Diabetologia,44, pp. 2018-2024 (2001).
Ladouceur, Gaetan, H., et al., “Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists”,Bioorganic&Medicinal Chemistry Letters,12, pp. 461-464 (2002).
Cascieri, Margaret, A., Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor,The Journal of Biological Chemistry,vol. 274, Issue of Mar. 26, pp. 8694-8697 (1999).
de Laszlo, Stephen, E., “Potent, Orally Absorbed Glucagon Receptor Antagonists”,Bioorganic&Medicinal Chemistry Letters,9, pp. 641-646 (1999).
Madsen, Peter, et al., “Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human glucagon Receptor Antagonists”,J. Med Chem,41, pp. 5150-5157 (1998).
Ling, Anthony, et al., “Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists”,J. Med. Chem,44, pp. 3141-3149 (2001).
Ling, Anthony, et al., “Human Glucagon Receptor Antagonists Based on Alkylidine Hydrazides”,Bioorganic&Medicinal Chemistry Letters,12, pp. 663-666 (2002).
Collins, Judith, L., “CP-99,711: A Non-Peptide Glucagon Receptor Antagonist”, Bioorganic & Medicinal Chemistry Letters, vol. 2, No. 9, pp. 915-918 (1992).
Parker, Janice, C., “Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and human Hepatocytes”,Diabetes,vol. 49, pp. 2079-2086 (Dec. 2000).
Connell, Richard, D., “Glucagon antagonists for the treatment of Type 2 diabetes”,Expert Opinion on Therapeutic patents,9(6), pp. 701-709 (1999).
Madsen, P., et al., “Advances in Non-Peptide Glucagon Receptor Antagonists”, Current Pharmaceutical Design, 5, pp. 683-691 (1999).
Campbell Elizabeth Louise
Chapman Kevin T.
Duffy Joseph L.
Kirk Brian A.
Konteatis Zenon
Billups Richard C.
Merck & Co. Inc
Stockton Laura L.
Winokur Melvin
LandOfFree
Cyanothiophene derivatives, compositions containing such... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyanothiophene derivatives, compositions containing such..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanothiophene derivatives, compositions containing such... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793718